Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 616-466-9 | CAS number: 77501-63-4
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Based on the PC data and the data reported in the EPA memorandum the below mentioned values were taken for DNEL calculation.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 5
- Absorption rate - inhalation (%):
- 100
Additional information
There are no studies in the open literature.
Relevant PC data:
Pysical state: solid (no information on particle size distribution; granulometry)
Vapour pressure: <1.2 x 10E-6 hPa (at 25oC)
Partition coefficient: LogP(o/w): 4.6
Water solubility: 0.11 mg/l
Not intended to be a surfactant
In an EPA Memorandum some information on toxicokinetic studies is given. (Memorandum dated March 2, 2000; subject: Lactofen – Toxicology Evaluation; from Elizabeth Mendez;PC code: 12888.)
A dermal penetration study in rats indicated 1-4% dermal absorption at the 4 and 10 hr. time points. Absorption of 4.6% was reported in a dermal penetration study in monkeys. Metabolism and pharmacokinetic was investigated in rats after oral dosing. Seventy two hours after administration >/= 97% of the radiolabel was recovered in the excreta (urine and feces). Urinary excretion comprised 39 – 56% of the dose while the fecal output totaled ca. 43 – 67% of the dose. While the parent compound, lactofen, was the major metabolite in the feces, the major metabolite in urine was acifluorfen which accounted for >90% of the radioactivity recovered in this fraction. The maximum percentage of administered radioactivity that accounted in a tissue sample was 0.55 – 0.75% in the liver.
Overall, based on the PC data and the data reported in the EPA memorandum the following values were taken for DNEL calculation. Absorption oral: 100%; dermal : 5% and inhalation 100% (worst case)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
